iOnctura

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round. 📣 Led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures , Inkef Capital, Vi Partners, Schroders Capital and 3B Future Health Fund I & II, this funding highlights a shared vision for the potential of our portfolio of precision oral small molecules.   This significant funding will:   🚀 Accelerate development of #roginolisib for the treatment of #uvealmelanoma through a randomized Phase II study 🚀 Broaden development of roginolisib for other cancer indications, including randomized Phase II studies in #NSCLC and primary #myelofibrosis 🚀 Progress #cambritaxestat and IOA-359 programs   Watch this space as we kick off a number of Phase II studies later in 2024.   Thank you to the team, investors and collaborators who continue to support and drive iOnctura forward. Link to press release in comments ⬇ #financing #oncology #drugdevelopment

Next week we will be dusting off our glad rags and heading down to Citeline's Scrip Awards where we've been nominated for two awards. A testiment to the amazing work of our team over the past year. Wish us luck 🍀 And we hope to see some of you there 🏆

Pleased to annouce our most recent research has just been published in AACR Journals Molecule Cancer Therapeutics. The research, done in partnership with Cancer Research UK (CRUK) and the group of Stuart Farrow, confirms the critical role of autotaxin in promoting a pro-tumorigenic microenvironment in pancreatic cancer. Thank you to the full team involved! Access the full publication via our website: 👉 https://lnkd.in/ergrb_PT

Interested in the biological mechanisms underlying the interaction between cancer cells and the tumor stroma? We are looking for a passionate postdoc to take pancreatic cancer and autotaxin research to the next level. Role is based in Amsterdam in the lab of Rodrigo Leite de Oliveira supported by KWF Kankerbestrijding. Details for applications below ⬇️

Grab yourself a coffee ☕, settle down and read this brilliant Drug Target Review interview with our CEO Catherine Pickering. Catherine talks about her mission to transform cancer treatment while championing diversity within the biotech industry. Read the full article here: 👉 https://lnkd.in/edUq4emP

Recently the Drug Discovery World team sat down with iOnctura CMO Michael L. to discuss advances in scientific research in the much-needed area of #pancreaticcancer.     Today, on World Pancreatic Cancer Day we reaffirm our commitment to finding a treatment to combat this devastating disease.    Read more on our research journey here Drug Discovery World - Breaking Barriers in Pancreatic Cancer 👉 https://lnkd.in/eimdmnYz   #WPCD 

Today is World Pancreatic Cancer Awareness Day.     Today, like every other day, the scientists and researchers at iOnctura continue to pursue small molecules for big impact in cancers which continue to evade treatment, like pancreatic cancer. There is still more to do.     We are proud to be pushing the boundaries of science with our Phase I autotaxin inhibitor #cambritaxestat in pancreatic cancer.    Read more about our research journey in our latest perspectives article, on pancreatic cancer, here: 👉 https://lnkd.in/edYQibME   #WPCD 

Happy to have secured third place in the European Lifestars Awards - Celebrating Life Science Leaders Series B Raise of the Year... And the only small molecule therapeutics company to be featured 👏

We enjoyed presenting our mission; small molecules making big impact, at the LSX - partnering for Life Science eXecutives investival showcase yesterday. CEO Catherine Pickering took to the biotech growth stage to share our growth plans and strategy. Thank you for having us!

We are at LSX Investival Showcase today 👋 Our CEO Catherine Pickering participated in a great panel this morning discussing innovative ways for biotechs to partner with pharma. If you would like to meet with us, head back to the Biotech Late Growth stage at 2pm to hear us present iOnctura’s strategy and vision. We look forward to seeing you then.